Compare FTCI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | AGEN |
|---|---|---|
| Founded | 2017 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4M | 124.4M |
| IPO Year | 2021 | 1999 |
| Metric | FTCI | AGEN |
|---|---|---|
| Price | $3.60 | $4.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $10.80 | ★ $14.50 |
| AVG Volume (30 Days) | 145.3K | ★ 806.9K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | $42,877,086.00 |
| Revenue This Year | $65.44 | $61.42 |
| Revenue Next Year | $45.97 | N/A |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | ★ 110.51 | 89.95 |
| 52 Week Low | $2.49 | $1.60 |
| 52 Week High | $12.75 | $7.34 |
| Indicator | FTCI | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 29.72 | 60.48 |
| Support Level | N/A | $3.92 |
| Resistance Level | $5.23 | $4.25 |
| Average True Range (ATR) | 0.33 | 0.31 |
| MACD | 0.11 | 0.07 |
| Stochastic Oscillator | 11.05 | 64.36 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.